Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 to the history; deletions remove a government-funding notice and the older Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding lapse notice and a revision note (v3.4.1); removed the previous revision note (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedUI updates in the history page include a Show glossary option and color-coded change highlights (green for additions, red for deletions) with a Revision: v3.4.0 banner. Additionally, the No FEAR Act data entry and the older Revision: v3.3.4 entry were removed.SummaryDifference0.6%

- Check42 days agoChange DetectedRevision: v3.3.4 was added to the page history, replacing the previous v3.3.3. No core content or study-related details were changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page now shows Revision: v3.3.3, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 have been removed.SummaryDifference0.1%

- Check92 days agoChange DetectedThe page history shows a new revision entry v3.3.2 added and an older revision v3.2.0 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.